Differential sensitivity to Escherichia coli infection in mice lacking tumor necrosis factor p55 or interleukin-1 p80 receptors

Archives of Surgery

Volumn 131, Issue 11, 1996, Pages 1216-1221

  Acton, Robert D ^a   Dahlberg, Peter S ^a   Uknis, Marc E ^a   Klaerner, Hans G ^a   Fink, Gregory S ^b   Norman, James G ^b   Dunn, David L ^a,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c University of Minnesota   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIOLYSIS; BLOOD CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; ESCHERICHIA COLI; GENE DISRUPTION; GRAM NEGATIVE INFECTION; INFECTION; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0029959305     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.1996.01430230098017     Document Type: Conference Paper

References (38)

1. Martin MA. Epidemiology and clinical impact of gram-negative sepsis. Infect Dis Clin North Am. 1991;5:739-752.
2. Bone RC. Gram-negative sepsis: a dilemma of modern medicine. Clin Microbiol Rev. 1993;6:57-68.
3. Battafarano RJ, Dunn DL. Immunotherapy in critically ill patients. In: Chernow B, ed. The Pharmacologic Approach to the Critically III Patient. 3rd ed. Baltimore, Md: Williams & Wilkins; 1994:365-377.
4. Dunn DL. Role of endotoxin and host cytokines in septic shock. Chest. 1991; 100(suppl):164S-168S.
5. Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989;321: 280-287.
6. Taveira da Silva AM, Kaulbach HC, Chuidian FS. Shock and multiple-organ dys-function after self-administration of salmonella endotoxin. N Engl J Med. 1993; 328:1457-1460.
7. Manthey CL, Vogel SN. Interactions of lipopolysaccharide with macrophages. Immunol Ser. 1994;60:63-81.
8. Lowry SF. Cytokine mediators of immunity and inflammation. Arch Surg. 1993; 128:1235-1241.
9. Pruitt JH, Copeland EM, Moldawer LL. Interleukin-1 and interleukin-1 antagonist in sepsis, systemic inflammatory response syndrome, and septic shock. Shock. 1995;3:235-251.
10. Tracy KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986;234:470-474.
11. Tracy KJ, Lowry SF, Fahey TJ, et al. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet. 1987;164:415-422.
12. Fong Y, Lowry SF. Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin Immunol Immunopathol. 1990;55:157-170.
13. Di Giovine FS, Duff GW. Interleukin 1: the first interleukin. Immunol Today. 1990;11:13-20.
14. Waage A, Espevik T. Interleukin 1 potentiates the lethal effect of tumor necrosis factor α-cachectin in mice. J Exp Med. 1988;167:1987-1992.
15. Moldawer LL. Biology of proinflammatory cytokines and their antagonist. Crit Care Med. 1994;22(suppl):S3-S7.
16. Zanetti G, Meumann D, Gerain J, et al. Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. J Immunol. 1992:148: 1890-1897.
17. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonist. J Immunol. 1993; 151:1548-1561.
18. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med. 1991;174:1483-1489.
19. Banner DW, D'Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation. Cell. 1993;73:431-445.
20. Gershenwald JE, Fong Y, Fahey TJ, et al. Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci U S A. 1990;87: 4966-4970.
21. Granowitz EV, Clark BD, Vannier E, Callahan MV, Dinarello CA. Effect of interleukin-1 (IL-1) blockade on cytokine synthesis, I: IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. Blood. 1992;79:2356-2363.
22. Giri JG, Wells J, Dower SK, et al. Elevated levels of shed type II IL-1 receptor in sepsis: potential role for type II receptor in regulation of IL-1 responses. J Immunol. 1994;153:5802-5809.
23. Battafarano RJ, Burd RS, Kurrelmeyer KM, Ratz CA, Dunn DL. Inhibition of splenic macrophage tumor necrosis factor a secretion in vivo by antilipopolysaccharide monoclonal antibodies. Arch Surg. 1994;129:179-186.
24. Evans KJ, Kaufmann MH. Establishment in culture of pluripotential cells from mouse embryo. Nature. 1981;292:154-156.
25. Robertson EJ. Embryo derived stem cells lines. In: Robertson EJ, ed. Teratocarcinomas and Embryonic Stem Cells: A Practical Approach. Oxford, England: IRL; 1987:71-112.
26. Waldman AS. Targeted homologous recombination in mammalian cells. Crit Rev Oncol Hematol. 1992;12:49-64.
27. Yeung RS, Penninger J, Mak TW. Genetically modified animals and immuno-deficiency. Curr Opin Immunol. 1993;5:585-594.
28. Norman JG, Fink G, Franz M, et al. Active interteukin-1 receptor required for maximal progression of acute pancreatitis. Ann Surg. 1996;223:163-169.
29. Mansour SL, Thomas KR, Capecchi MR. Disruption of the protooncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature. 1988;336:348-352.
30. Fleffer K, Matsuyama T, Kundig TM, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L monocytogenes infection. Cell. 1993;73:457-467.
31. Pennington JE. Therapy with antibody to tumor necrosis factor in sepsis. Clin Infect Dis. 1993;17(suppl):S515-S519.
32. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature. 1990; 348:550-551.
33. Fischer CJ, Opal SM, Dhainaut JF, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med. 1993;21:318-327.
34. 2 fragment of an anti-tumor necrosis factor a monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels. Shock. 1994;1:237-245.
35. Fisher CJ, Dhainaut JFA, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA. 1994;271:1836-1843.
36. Rothe J, Lesslauer W, Lotscher H, et al. Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993;364:798-802.
37. Zheng H, Fletcher D, Kozak W, et al. Resistance to fever induction and impaired acute-phase response in interleukin-1β-deficient mice. Immunity. 1995; 3:9-19.
38. Nakano Y, Onozuka K, Terada Y, Shinomiya H, Nakano M. Protective effect of recombinant tumor necrosis factor-α in murine salmonellosis. J Immunol. 1990; 144:1935-1941.